Skip to main content

Table 2 Toxic profile of targeted therapy tested in anaplastic thyroid cancer

From: Recent advances in the management of anaplastic thyroid cancer

Evaluated drug(s) AEs grade I/II Recurrence (%) AEs grade III/IV/V Recurrence (%) REFERENCE(s)
Lenvatinib A Fatigue, Hypertension (38–53), Decreased appetite (25–64), Nausea (13–59), Proteinuria (19–53), Mucositis/Stomatitis (25–41) Hypertension (6–29), Decreased appetite (0–18), Thrombocytopenia (0–12), Fatigue (6) Tahara et al.
Iyer et al.
Sorafenib A Weight decreased (50–55), Rash/desquamation (40–55), Fatigue (30–55), Anemia (0–55), Palmar-plantar erythrodysesthesia (0–50) Hypertension, AST increase (0–20), Rash/desquamation (0–15), Hyponatremia (0–10), Hypophosphatemia (0–10) Savvides et al.
Ito et al.
Sunitinib B Asthenia/fatigue (56), Mucosal AEs (53), Diarrhea (48), Cutaneous AEs (44), Hemorrhage (37) Asthenia/fatigue (27), HFS (18), Neutropenia (17), Diarrhea (13), Mucosal AEs (11) Ravaud et al.
Pazopanib A Fatigue (73), Anorexia (53), Diarrhea (47), Hypertension, Nausea (40), Protein urine positivity, Skin Hypopigmentation (33) Hypertension, Pharyngo-laryngeal pain (13), Alanine/asprtate aminotransferase increase, Atrial fibrillation, Leukocyte/Lymphocyte count decrease, Thrombosis (7) Bible et al.
Gefitinib B Rash (44), Diarrhea (37), Nausea (19), Anorexia (11) Rash (7), Diarrhea (4) Pennell et al.
Vemurafenib A Rash, Decreased appetite, Dysphagia (43), Arthralgia, Candida infection, Photosensitivity reaction, Cough, Cognitive disorder, Pruritus, Vomiting, Pyrexia, Palmar-plantar erythrodysesthesia Syndrome (29) Fatigue (29), Rash, Pyrexia, Dehydration, Cutaneous squamous cell carcinoma (14) Hyman et al.
Imatinib A Myalgia/arthralgia, Abnormal liver function test (73), Electrolyte abnormality (64), Fatigue, Anemia (55), Cough, Lymphopenia, Edema, Dyspnea (45), Nausea/Vomiting, Hyperglycemia (36) Lymphopenia (45), Edema (27), Electrolyte abnormality, Syncope, Electrolyte abnormality, Nausea/Voimiting, Anemia (18) Ha et al.
Axitinib B Fatigue, Diarrhea (45), Nausea (33), Anorexia (30), Stomatitis (25), Weight decrease (22) Hypertension (12), Proteinuria, Fatigue (5), Headache, Weight decrease, Diarrhea (3) Cohen et al.
Dabrafenib +
Trametinib A
Fatigue (19–38), Nausea (25–31), Vomiting (13–25), Pyrexia (6–31), Constipation (6–25) Anemia (6–13), Hypernatriemia (0–13), Fatigue (6), Diarrhea, Hypercalcemia, Hyperglicemia (0–6) Subbiah et al.
Iyer et al.
Everolimus B Stomatitis/mucositis (46–69), Anorexia (26–42), Cough (0–60), Hyperglicemia (10–49), Anemia (0–57), Fatigue (0–51) Mucositis (11–15), Hypertension (11), Diarrhea (10), Neutropenia (5), Anorexia (2–4) Lim et al.
Schneider et al.
Spartalizumab B Diarrhea, Pruritus (12), Fatigue, Pyrexia (7), Anemia, Asthenia, Myalgia, Rash (5) Anemia (5), Rash (2) Capdevila et al.
Fosbretabulin A Headache (51), Lymphopenia (34), Pain (other than tumor pain and headache) (32), Prolonged QTc (28), Tumor Pain (25) Lymphopenia (11), Tumor Pain (4), Pain (other than tumor pain and headache)(1) Mooney et al.C
Sorafenib +
Temsirolimus B
NA Hyperglicemia (19), Fatigue (14), Anemia (11), Alanine-aminotransferase increase, Oral mucositis (8) Sherman et al.
Fosbretabulin +
CP A
Alopecia (31), Fatigue, Hypertension (29), Nausea (24), Diarrhea (22), Anemia, Headache (20) Neutropenia (43), Leukopenia (26), Anemia (16), Tumor pain (6 Sosa et al.
Efatutazone +
Paclitaxel A
Edema (40), Anemia, Fatigue (33), Nausea, Weight increase, Dyspnea (27), Insomnia, Back pain, Abdominal pain, Cough (20) Edema (13), Leukopenia, Neutrophil count decrased, Fatigue, Pneumonia, Hypovolemia (7) Smallridge et al.D
  1. Abbreviations: AEs Adverse Events; CPPaclitaxel followed by Carboplatin
  2. Notes: AAEs evaluated only in ATC patients
  3. BAEs evaluated both in ATC and other histotype tumors
  4. CRecurrence of AEs is expressed as the total number of events occurred during the study (all grade registered AEs were 477)
  5. DAEs recurrence refers to all the enrolled patients, independently of the different therapeutic regimen